Multiple Dose Ethnobridging PK Study in Healthy Subjects

NCT03750565 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Inflammatory Bowel Diseases
IBD

Interventions

DRUG: TD-1473 - Dose A
DRUG: TD-1473 - Dose B
DRUG: TD-1473 - Dose C
DRUG: Placebo

Sponsor

Theravance Biopharma